v3.26.1
SUMMARY OF NUMBER OF OPTIONS GRANTED (Details) - Stock Option Plan [Member] - USD ($)
 9 Months Ended 12 Months Ended
Feb. 01, 2026
Aug. 01, 2025
Apr. 30, 2026
Jul. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Number of options, beginning balance   13,251 13,251  
Weighted average exercise price, beginning balance   $ 896.61 $ 896.61  
Weighted average remaining contractual term (in years)     4 years 7 months 9 days 1 year 7 months 13 days
Aggregate intrinsic value, beginning balance    
Number of options, granted 291,000 37,700 328,700 [1]  
Weighted average exercise price, granted $ 5.59 $ 12.50 $ 6.38 [1]  
Weighted average remaining contractual term (in years), granted [1]     4 years 8 months 12 days  
Aggregate intrinsic value, granted [1]      
Number of options, expired     (4,477)  
Weighted average exercise price, expired     $ 636  
Number of options, ending balance     337,474 13,251
Weighted average exercise price, ending balance     $ 33.06 $ 896.61
Aggregate intrinsic value, ending balance    
Number of options, exercisable     22,912  
Weighted average exercise price, exercisable     $ 403.06  
Weighted average remaining contractual term (in years), exercisable     3 years 1 month 24 days  
Aggregate intrinsic value, exercisable      
[1] On August 1, 2025, the Company granted 37,700 stock options to employees and members of the scientific advisory board at an exercise price of $12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $218,784. The fair value of options granted during the nine-month period ended April 30, 2026 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 116%, expected term of 5.0 years, risk-free interest rate of 3.98%, dividend yield of 0%, and a stock price of $7.50 on the grant date.